Hall of Fame

This report details a strategic Structure-Based Drug Design (SBDD) project focused on developing novel inhibitors of UBE2N to address the significant clinical challenge of PARP inhibitor (PARPi) resistance in ovarian cancer. The project utilizes an integrated computational workflow, including BioSolveIT's SeeSAR, InfiniSee, FastGrow and HYDE assessment for rapid virtual screening and interactive lead design, followed by Molecular Dynamics (MD) simulations for rigorous validation. The goal is to identify new non-covalent potentially and stable UBE2N inhibitors for subsequent cell-based testing, ultimately contributing to more effective combination therapies for ovarian cancer patients who have developed resistance to PARP inhibitors. The next planned...